# FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

> **NCT04710524** · PHASE2 · UNKNOWN · sponsor: **Future Medicine** · enrollment: 60 (estimated)

## Conditions studied

- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** FM101 150 mg BID
- **DRUG:** FM101 300 mg BID

## Key facts

- **NCT ID:** NCT04710524
- **Lead sponsor:** Future Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-10
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04710524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04710524, "FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04710524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*